Comparison of Rifaximin and Trimebutin Maleate Treatment for Irritable Bowel Syndrome with Constipation and Diarrhea

Abstract

Introduction: Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with changes in bowel habits, abdomi- nal pain, and gas without any organic pathology. IBS is divided into three types as constipation – IBS (IBS-C), diarrhea – IBS (IBS-D), and mixed. Rifaximin is an antibiotic that improves IBS symptoms by improving the flora in the intestine. The aim of the study was to determine whether the treatment of rifaximin is superior to treatment. Methods: This study performed retrospectively and patients were divided into two groups as IBS-C and IBS-D. Each group was divided into two groups as rifaximin and Trimebutin Maleate treatment. Rifaximin at a dose of 200 mg, 3×2 daily for 15 days. Trimebutin Maleate group includes lifestyle modification and Trimebutin Maleate 200 mg 3×1. At the end of the treat- ment and after 20 days, the patients were re-evaluated. Results: A total of 179 subjects had examined. In terms of IBS symptoms; bloating, abdominal pain, and stool consistency, both treatments are effective as long as patients continue treatment; however, 20 days after the end of the treatment, rifax- imin treatment was found to be more effective than trimebutin maleate treatment. Discussion and Conclusion: The use of rifaximin provides significant long-term improvement in both diarrhea and consti- pation IBS patients compared to Trimebutin Maleate treatment.